Stock RLAY RELAY THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Relay Therapeutics, Inc.

Equities

RLAY

US75943R1023

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
6.37 USD +3.49% Intraday chart for Relay Therapeutics, Inc. +6.88% -42.14%
03-12 Transcript : Relay Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 07:30 AM
02-23 Relay Therapeutics Q4 Loss Widens, Reports No Revenue MT

Business Summary

Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company is focused on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The Company’s Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608, Lirafugratinib (RLY-4008), and Migoprotafib (GDC-1971). RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor. RLY-4008, is a potent, selective, and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers. GDC-1971 is an inhibitor of Src homology region 2 domain-containing phosphatase-2 (SHP2), as a monotherapy in patients with advanced or metastatic solid tumors.

Number of employees: 323

Sales per Business

USD in Million2022Weight2023Weight Delta
Dynamo Platform
100.0 %
1 100.0 % 26 100.0 % +1,749.82%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
1 100.0 % 26 100.0 % +1,749.82%

Managers

Managers TitleAgeSince
Sanjiv Patel CEO
 Chief Executive Officer 50 28/02/17
Mark Murcko FOU
 Founder 64 03/05/15
Alexis Borisy FOU
 Founder 52 03/05/15
Thomas Catinazzo DFI
 Director of Finance/CFO 47 31/03/18
Imogen Pryce COO
 Chief Operating Officer - -
Ben Wolf CTO
 Chief Tech/Sci/R&D Officer - 31/10/19
Andy Porter ADM
 Chief Administrative Officer - 31/10/19
Donald Bergstrom CTO
 Chief Tech/Sci/R&D Officer 52 31/03/18
Jeanne Gray HRO
 Human Resources Officer - -
Patrick Riley PRN
 Corporate Officer/Principal - 09/05/21

Members of the board

Members of the board TitleAgeSince
Douglas Ingram BRD
 Director/Board Member 61 31/05/19
Linda Hill BRD
 Director/Board Member 67 08/10/18
Jami Rubin BRD
 Director/Board Member 60 30/09/19
Alexis Borisy FOU
 Founder 52 03/05/15
Laura Shawver BRD
 Director/Board Member 66 28/02/17
Mark Murcko FOU
 Founder 64 03/05/15
Sanjiv Patel CEO
 Chief Executive Officer 50 28/02/17
Sekar Kathiresan BRD
 Director/Board Member 52 24/07/22

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 132,334,861 127,462,859 ( 96.32 %) 0 96.32 %

Shareholders

NameEquities%Valuation
SB Investment Advisers (UK) Ltd.
21.27 %
27,904,963 21.27 % 232 M $
Vanguard Fiduciary Trust Co.
8.119 %
10,650,387 8.119 % 88 M $
BlackRock Advisors LLC
6.648 %
8,720,793 6.648 % 72 M $
T. Rowe Price International Ltd.
6.542 %
8,581,167 6.542 % 71 M $
Casdin Capital LLC
5.632 %
7,387,943 5.632 % 61 M $
JPMorgan Investment Management, Inc.
4.624 %
6,065,595 4.624 % 50 M $
Bellevue Asset Management AG
4.525 %
5,936,082 4.525 % 49 M $
STATE STREET CORPORATION
3.738 %
4,903,578 3.738 % 41 M $
BVF, Inc.
3.026 %
3,970,045 3.026 % 33 M $
ArrowMark Colorado Holdings LLC
2.984 %
3,914,246 2.984 % 32 M $

Company contact information

Relay Therapeutics, Inc.

399 Binney Street 2nd floor

02139, Cambridge

+

http://www.relaytx.com
address Relay Therapeutics, Inc.(RLAY)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Relay Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
6.37 USD
Average target price
23.05 USD
Spread / Average Target
+261.92%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
RELAY THERAPEUTICS, INC. Stock Relay Therapeutics, Inc.
-42.14% 843M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. RLAY Stock
  4. Company Relay Therapeutics, Inc.